No Benefit to Salvage Transplant in R/R Multiple Myeloma : v

Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.

Related Keywords

Salt Lake City , Utah , United States , Heidelberg , Baden Wüberg , Germany , University Of Utah , German , American , Manni Mohyuddin , Marc Andrea Baertsch , University Hospital Heidelberg , German Cancer Research Center , American Society Of Hematology , American Society , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Transplantation , Transplant , Biologic Therapy , Iologics , Transplantation Of Stem Cells , Ransplantation Of Hematopoietic Stem Cells , Hematopoietic Stem Cell Transplant , Stem Cell Transplantation , Stem Cell Therapy , Tem Cell Haematopoietic Stem Transplant ,